Literature DB >> 33452459

KNSTRN promotes tumorigenesis and gemcitabine resistance by activating AKT in bladder cancer.

Yaoyi Xiong1, Lingao Ju2,3,4, Lushun Yuan5, Liang Chen1,6, Gang Wang2,3,4, Huimin Xu1, Tianchen Peng1, Yongwen Luo1, Yu Xiao7,8,9,10,11, Xinghuan Wang12,13,14.   

Abstract

KNSTRN is a component of the mitotic spindle, which was rarely investigated in tumorigenesis. AKT plays an essential role in tumorigenesis by modulating the phosphorylation of various substrates. The activation of AKT is regulated by PTEN and PIP3. Here, we prove KNSTRN is positively correlated with malignancy of bladder cancer and KNSTRN activates AKT phosphorylation at Thr308 and Ser473. More importantly, our study reveals that both KNSTRN and PTEN interact with PH domain of AKT at cell membrane. The amount of KNSTRN interacted with AKT is negatively related to PTEN. Furthermore, PIP3 pull-down assay proves that KNSTRN promoted AKT movement to PIP3. These data suggest KNSTRN may activate AKT phosphorylation by promoting AKT movement to PIP3 and alleviating PTEN suppression. Based on the activation of AKT phosphorylation, our study demonstrates that KNSTRN promotes bladder cancer metastasis and gemcitabine resistance in vitro and in vivo. Meanwhile, the effect of KNSTRN on tumorigenesis and gemcitabine resistance could be restored by AKT specific inhibitor MK2206 or AKT overexpression. In conclusion, we identify an oncogene KNSTRN that promotes tumorigenesis and gemcitabine resistance by activating AKT phosphorylation and may serve as a therapeutic target in bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33452459     DOI: 10.1038/s41388-020-01634-z

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  2 in total

1.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

2.  Analysis of gene co‑expression network reveals prognostic significance of CNFN in patients with head and neck cancer.

Authors:  Baoling Liu; Guanhong Huang; Hongming Zhu; Zhaoming Ma; Xiaokang Tian; Li Yin; Xingya Gao; Xia He
Journal:  Oncol Rep       Date:  2019-02-18       Impact factor: 3.906

  2 in total
  8 in total

1.  Inhibition of PP2A by LB100 sensitizes bladder cancer cells to chemotherapy by inducing p21 degradation.

Authors:  Song Gao; Liping Shan; Mo Zhang; Yan Wang; Xi Zhan; Yalei Yin; Zhonghao Jiang; Xinyi Tao; Xinyu Li; Mingliang Ye; Yang Liu
Journal:  Cell Oncol (Dordr)       Date:  2022-09-22       Impact factor: 7.051

2.  Determination of WWOX Function in Modulating Cellular Pathways Activated by AP-2α and AP-2γ Transcription Factors in Bladder Cancer.

Authors:  Damian Kołat; Żaneta Kałuzińska; Andrzej K Bednarek; Elżbieta Płuciennik
Journal:  Cells       Date:  2022-04-19       Impact factor: 7.666

3.  Genome-Wide CRISPR Screening Identifies DCK and CCNL1 as Genes That Contribute to Gemcitabine Resistance in Pancreatic Cancer.

Authors:  Hai Yang; Bin Liu; Dongxue Liu; Zhirong Yang; Shuman Zhang; Pengyan Xu; Yuming Xing; Isabella Kutschick; Susanne Pfeffer; Nathalie Britzen-Laurent; Robert Grützmann; Christian Pilarsky
Journal:  Cancers (Basel)       Date:  2022-06-27       Impact factor: 6.575

4.  Phosphorylation of small kinetochore-associated protein induced by GSK3β promotes cell migration and invasion in esophageal cancer.

Authors:  Bo Qin; Zhu Zhu; Fanxiang Yin; Dan Yan; Jiajia Wan; Meng Dong; Zhengyang Wang
Journal:  Cell Cycle       Date:  2022-02-24       Impact factor: 5.173

5.  Analysis of the lncRNA-miRNA-mRNA Network Reveals a Potential Regulatory Mechanism of EGFR-TKI Resistance in NSCLC.

Authors:  Dandan Ding; Jufeng Zhang; Zhiming Luo; Huazhen Wu; Zexiao Lin; Weicheng Liang; Xingyang Xue
Journal:  Front Genet       Date:  2022-04-29       Impact factor: 4.772

6.  Non-invasive diagnosis and surveillance of bladder cancer with driver and passenger DNA methylation in a prospective cohort study.

Authors:  Yu Xiao; Lingao Ju; Kaiyu Qian; Wan Jin; Gang Wang; Yan Zhao; Wei Jiang; Nan Liu; Kai Wu; Minsheng Peng; Rui Cao; Sheng Li; Hongjie Shi; Yan Gong; Hang Zheng; Tongzu Liu; Yongwen Luo; Haoli Ma; Luyuan Chang; Gang Li; Xinyue Cao; Ye Tian; Zilin Xu; Zhonghua Yang; Liuying Shan; Zhongqiang Guo; Dongai Yao; Xianlong Zhou; Xintong Chen; Zicheng Guo; Dongmei Liu; Song Xu; Chundong Ji; Fang Yu; Xin Hong; Jun Luo; Hong Cao; Yi Zhang; Xinghuan Wang
Journal:  Clin Transl Med       Date:  2022-08

7.  Single Cell Analysis of Cultivated Fibroblasts from Chronic Pancreatitis and Pancreatic Cancer Patients.

Authors:  Yoshiaki Sunami; Yijun Chen; Bogusz Trojanowicz; Matthias Sommerer; Monika Hämmerle; Roland Eils; Jörg Kleeff
Journal:  Cells       Date:  2022-08-19       Impact factor: 7.666

8.  Allyl-, Butyl- and Phenylethyl-Isothiocyanate Modulate Akt-mTOR and Cyclin-CDK Signaling in Gemcitabine- and Cisplatin-Resistant Bladder Cancer Cell Lines.

Authors:  Jochen Rutz; Sebastian Maxeiner; Timothy Grein; Marlon Sonnenburg; Salma El Khadir; Nino Makhatelashvili; Johanna Mann; Hui Xie; Jindrich Cinatl; Anita Thomas; Felix K-H Chun; Axel Haferkamp; Roman A Blaheta; Igor Tsaur
Journal:  Int J Mol Sci       Date:  2022-09-20       Impact factor: 6.208

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.